Added immunotherapy after lung cancer surgery showed no clear survival advantage
For operable non-small cell lung cancer, a trial network found no clear survival benefit from adding postoperative immunotherapy to chemotherapy plus immunotherapy before surgery. The estimates remain compatible with different effects.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The analysis found no clear improvement in event-free survival or overall survival when postoperative immunotherapy was added to chemotherapy plus immunotherapy given before surgery. Event-free survival measures time without a study-defined event. The uncertainty around these comparisons means the findings do not establish that adding treatment has no effect or that the strategies are equivalent.
Some treatment strategies could not be compared within the trial network. The authors called for direct comparisons, and the abstract does not report follow-up lengths or define the events included in event-free survival.
What researchers found
Added postoperative immunotherapy
Versus preoperative chemotherapy plus immunotherapy alone: hazard ratio 0.97, 95% confidence interval 0.67 to 1.41. Follow-up duration was not reported; this compares event rates over time.
The comparison concerns treatment timing
The central question was whether continuing immunotherapy after surgery adds benefit when patients already received chemotherapy plus immunotherapy beforehand. The findings concern this specific cancer population and treatment sequence, rather than immunotherapy in general.
Uncertain differences do not establish equal outcomes
Overall survival differences were also statistically uncertain. Added treatment did not show a significant increase in reported treatment-related adverse events, but a nonsignificant safety comparison does not establish identical harms between treatment strategies.
The original publication
Immune checkpoint inhibitors as neoadjuvant therapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis.
Aburaki R, Fujiwara Y, Haketa S et al.
J Natl Cancer Inst · 2025
- PubMed ID
- 40701555
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.